As of 2026-04-11, the Intrinsic Value of Biotech Growth Trust PLC (BIOG.L) is (8,339.57) GBP. This BIOG.L valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 1,286.00 GBP, the upside of Biotech Growth Trust PLC is -748.50%.
The range of the Intrinsic Value is (14,302.81) - (6,032.22) GBP
Based on its market price of 1,286.00 GBP and our intrinsic valuation, Biotech Growth Trust PLC (BIOG.L) is overvalued by 748.50%.
Note: result may not be accurate due to the invalid valuation result of DCF model.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (14,302.81) - (6,032.22) | (8,339.57) | -748.5% |
| DCF (Growth 10y) | (6,146.13) - (13,352.33) | (8,182.69) | -736.3% |
| DCF (EBITDA 5y) | (2,997.99) - (5,753.19) | (1,234.50) | -123450.0% |
| DCF (EBITDA 10y) | (4,067.79) - (6,647.40) | (1,234.50) | -123450.0% |
| Fair Value | -2,772.80 - -2,772.80 | -2,772.80 | -315.61% |
| P/E | (1,255.52) - (1,390.84) | (1,355.90) | -205.4% |
| EV/EBITDA | (895.83) - (1,271.77) | (1,034.04) | -180.4% |
| EPV | (720.74) - (931.43) | (826.08) | -164.2% |
| DDM - Stable | (637.09) - (1,377.38) | (1,007.23) | -178.3% |
| DDM - Multi | (2,639.59) - (4,489.92) | (3,329.48) | -358.9% |
| Market Cap (mil) | 247.56 |
| Beta | 0.65 |
| Outstanding shares (mil) | 0.19 |
| Enterprise Value (mil) | 275.27 |
| Market risk premium | 5.98% |
| Cost of Equity | 13.72% |
| Cost of Debt | 5.50% |
| WACC | 9.60% |